A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre) in the Treatment of Mild-to-high Hypertriglyceridemia.
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2014
At a glance
- Drugs NKPL 66 (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Acronyms TRIFECTA
- Sponsors Acasti Pharma
- 21 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 04 Dec 2012 Planned end date changed from 1 Nov 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.